Literature DB >> 27697513

Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers.

Sandeep Kumar1, Gaurav Bhanjana2, Arvind Kumar2, Kapila Taneja2, Neeraj Dilbaghi2, Ki-Hyun Kim3.   

Abstract

The use of nanocarriers to enhance drug delivery efficacy has been increasing in the healthcare field due to their tunable surface properties. In this study, ceftriaxone-loaded solid lipid nanoparticles (CL-SLNPs) were synthesized using a water-in-oil-in-water (w/o/w) type double emulsification method. The formulation was optimized using response surface methodology (RSM) and was characterized using transmission electron microscopy (TEM), photon correlation spectroscopy (PCS), and UV-vis and Fourier transform infrared (FTIR) spectroscopy. The CL-SLNPs were of spherical shape, 15-20nm in size, and retained the properties of the drug or other constituents/ingredients after loading. The prepared nanoformulation offered sustained drug release after 24h, while ceftriaxone sodium followed a burst release. Antibacterial activity of the nanoformulation was evaluated against different gram-positive and gram-negative bacterial strains. The minimum inhibitory concentration of CL-SLNPs against Pseudomonas aeruginosa was determined as 31μg/mL.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antibacterial; Ceftriaxone sodium; Emulsification; Nanoformulation; Solid lipid nanoparticles

Mesh:

Substances:

Year:  2016        PMID: 27697513     DOI: 10.1016/j.chemphyslip.2016.09.002

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  9 in total

1.  Design and Optimization of New Enteric Nanoparticles of Ceftriaxone for Oral Delivery: In vitro and in vivo Assessments.

Authors:  Amir Maghrabia; Mariza Boughdady; Mahasen Meshali
Journal:  Int J Nanomedicine       Date:  2021-08-28

2.  Synthesis, Spectroscopic Studies for Five New Mg (II), Fe (III), Cu (II), Zn (II) and Se (IV) Ceftriaxone Antibiotic Drug Complexes and Their Possible Hepatoprotective and Antioxidant Capacities.

Authors:  Samy M El-Megharbel; Safa H Qahl; Fatima S Alaryani; Reham Z Hamza
Journal:  Antibiotics (Basel)       Date:  2022-04-20

Review 3.  Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.

Authors:  G Y Wang; S L Rayner; R Chung; B Y Shi; X J Liang
Journal:  Mater Today Bio       Date:  2020-05-04

Review 4.  Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems.

Authors:  Osama A Madkhali
Journal:  Molecules       Date:  2022-02-24       Impact factor: 4.411

Review 5.  Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes.

Authors:  Ashagrachew Tewabe Yayehrad; Gebremariam Birhanu Wondie; Tesfa Marew
Journal:  Infect Drug Resist       Date:  2022-02-05       Impact factor: 4.003

Review 6.  Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence.

Authors:  Lide Arana; Lucia Gallego; Itziar Alkorta
Journal:  Nanomaterials (Basel)       Date:  2021-05-10       Impact factor: 5.076

7.  Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules.

Authors:  Noor Akbar; Zara Aslam; Ruqaiyyah Siddiqui; Muhammad Raza Shah; Naveed Ahmed Khan
Journal:  AMB Express       Date:  2021-07-10       Impact factor: 3.298

8.  Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study.

Authors:  Sahar Ebrahimi; Nafiseh Farhadian; Mohammad Karimi; Mohsen Ebrahimi
Journal:  Antimicrob Resist Infect Control       Date:  2020-02-10       Impact factor: 4.887

Review 9.  The contribution of nano-based strategies in overcoming ceftriaxone resistance: a literature review.

Authors:  Ashagrachew Tewabe; Tesfa Marew; Gebremariam Birhanu
Journal:  Pharmacol Res Perspect       Date:  2021-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.